One To Watch

Valneva

Company Overview

A French specialty vaccine company navigating a pivotal transition from its three marketed travel vaccines toward a potentially transformative Pfizer-partnered Lyme disease vaccine that posted Phase III efficacy above 70% in March 2026. Valneva's commercial base spans chikungunya (IXCHIQ), Japanese encephalitis (IXIARO), and cholera (DUKORAL) vaccines, but the IXCHIQ franchise has been materially weakened by regulatory setbacks in the US and restrictions on elderly use in Europe. The strategic center of gravity is now squarely on LB6V and a nascent Shigella program licensed from LimmaTech Biologics.

Headquarters and Global Presence

Valneva is headquartered in Saint-Herblain, near Nantes, France, and is listed on Euronext Paris. Following a restructuring announced in late 2025, it is consolidating French manufacturing operations in Lyon after closing its Nantes site. It maintains commercial and regulatory presence across Europe and has licensing partnerships extending its reach into Asia and Latin America.

Founding and History

Valneva was formed in 2013 through the merger of Intercell and Vivalis, two European vaccine specialists. The company secured FDA approval for IXCHIQ in November 2023 — the world's first licensed chikungunya vaccine — a milestone that subsequently unravelled when the FDA suspended the biologics license in August 2025 over safety concerns. Valneva withdrew both its BLA and IND filings for IXCHIQ in the US in January 2026, effectively exiting the American chikungunya market.

Therapy Areas and Focus

Valneva occupies a deliberately narrow niche: prophylactic vaccines for infectious diseases where commercial vaccines either do not exist or are inadequate. Chikungunya, Lyme disease, and Shigella all fit that profile — diseases with large and growing at-risk populations, limited prevention options, and challenging development histories that have deterred most large vaccine players. The Lyme opportunity is particularly significant given approximately 476,000 estimated US cases annually and no licensed vaccine available since GlaxoSmithKline withdrew LYMErix in 2002.

Technology Platforms and Modalities

Valneva's core technical competency is whole-pathogen and protein-subunit vaccine manufacturing, rather than mRNA or viral vector platforms. IXCHIQ is a live-attenuated single-dose vaccine — a format that drives the strong immunogenicity but also the neurological safety signals that have complicated its regulatory trajectory. LB6V (VLA15) is a six-valent protein subunit vaccine targeting six OspA serotypes of Borrelia, the bacterium behind Lyme disease; the multivariant design is the key differentiator over prior single-valent attempts. The Shigella4V candidate, in-licensed from LimmaTech, adds a conjugate vaccine modality to the portfolio.

Key Pipeline and Programs

LB6V (also designated VLA15), the Pfizer-partnered Lyme disease vaccine, is the company's defining asset. It is a recombinant six-valent OspA-based protein subunit vaccine targeting the six major Borrelia OspA serotypes prevalent in North America and Europe. The Phase III VALOR trial (NCT05477524) reported topline results in March 2026 showing greater than 70% efficacy against confirmed Lyme disease in individuals aged five and above, with a clean safety profile. Pfizer, as trial sponsor, is planning regulatory submissions; if approved, LB6V would be the first Lyme vaccine on market in over two decades.

Shigella4V is a four-valent conjugate vaccine candidate in-licensed from LimmaTech Biologics under an exclusive global agreement signed in August 2024. Shigella causes an estimated 160 million diarrheal illness episodes annually, disproportionately in low- and middle-income countries and in travelers. The program remains at an earlier stage, with data readouts flagged as a near-term catalyst for 2026.

IXCHIQ, the live-attenuated chikungunya vaccine, remains commercially active in markets outside the US. A pilot real-world vaccination program in Brazil with Instituto Butantan vaccinated over 30,000 adults between February and May 2026, with Brazil's regulator subsequently authorizing local Butantan manufacturing. An exclusive Asia licensing deal with Serum Institute of India, signed in December 2024, extends IXCHIQ's geographic reach, though EMA restrictions on elderly use and ongoing PSUR surveillance through June 2026 constrain European uptake.

Recent Developments

In March 2026, Valneva and Pfizer announced that the VALOR Phase III trial met its primary endpoint with greater than 70% vaccine efficacy for LB6V, triggering Pfizer's regulatory filing plans and marking the most significant clinical milestone in Valneva's history. The EMA's PRAC in March 2026 also recommended a product information update for IXCHIQ following a reported case of aseptic meningitis in a healthy young adult — adding to the May 2025 elderly-use restriction that followed 17 serious adverse events including two deaths. Q1 2026 revenues fell nearly 40% year-on-year to €30.9 million, reflecting restructuring costs and IXCHIQ sales pressure, though the company guided for full-year 2026 revenues of €155–170 million. The Nantes site closure and Lyon consolidation, announced in November 2025, represent the structural response to that commercial pressure.

Key Personnel

Thomas Lingelbach serves as President and Chief Executive Officer, having led the company through both the IXCHIQ approval and subsequent US market withdrawal. Dipal Patel, recruited from GSK, joined as Chief Commercial Officer and management board member in November 2022, bringing experience from one of the world's largest vaccine businesses at a moment when Valneva needs to build commercial infrastructure for a potential Lyme launch. The company's management board oversees an organization navigating simultaneous restructuring, pharmacovigilance scrutiny, and a pre-submission regulatory process for its most consequential asset.

Strategic Partnerships

The Pfizer collaboration on LB6V is the axis around which Valneva's near-term value turns; Pfizer funds and leads the VALOR trial and will sponsor regulatory submissions, giving Valneva a large-pharma commercialization engine for what could be a blockbuster product. The August 2024 LimmaTech licensing deal adds Shigella4V to the pipeline on an exclusive global basis. In Asia, the December 2024 exclusive license with Serum Institute of India covers IXCHIQ supply, while the Instituto Butantan partnership opens a manufacturing pathway in Brazil.

FAQ Section

Highly dependent. The US withdrawal of IXCHIQ's biologics license in January 2026, combined with EMA restrictions on elderly use, has structurally reduced the chikungunya franchise's ceiling. With Q1 2026 revenues already down 40% year-on-year and a restructuring underway, LB6V's commercial success is effectively non-optional for Valneva's medium-term financial health. Pfizer's sponsorship of regulatory filings provides execution support, but Valneva's royalty and milestone position means the company is a leveraged bet on that program's outcome.

GlaxoSmithKline's LYMErix was withdrawn in 2002 under commercial and litigation pressure despite demonstrated efficacy, leaving a two-decade gap. Earlier candidates targeted a single OspA serotype, limiting geographic coverage. LB6V's six-valent design targets the six dominant Borrelia OspA serotypes across North America and Europe, addressing the strain diversity that undermined previous attempts and broadening the addressable population substantially.

Valneva's structural advantage is focus: it concentrates exclusively on pathogens where no vaccine exists or where the existing option is inadequate, rather than competing in crowded respiratory or pediatric markets. Its willingness to advance difficult programs — a live-attenuated chikungunya vaccine, a six-valent Lyme candidate — reflects genuine technical depth in whole-pathogen and protein-subunit manufacturing. The trade-off is that smaller revenue base means individual safety signals, like those seen with IXCHIQ, carry disproportionate financial consequences.

The FDA suspended IXCHIQ's biologics license in August 2025 following safety concerns, prompting Valneva to voluntarily withdraw both its BLA and IND in January 2026, effectively closing the US market. IXCHIQ remains commercially active in Europe, though EMA restricted its use in elderly populations in May 2025 after reviewing 17 serious adverse events including two deaths, and a March 2026 product information update flagged an additional aseptic meningitis case. The Brazil pilot program and Serum Institute of India Asia license represent the commercial growth story now being built outside Western regulatory frameworks.

Chikungunya prevention remains commercially active across Europe, Asia, and Latin America despite US market exit. The Shigella4V program, in-licensed from LimmaTech Biologics in August 2024, targets one of the leading causes of diarrheal disease globally, with data expected in 2026. Japanese encephalitis (IXIARO) and cholera (DUKORAL) round out the marketed travel vaccine portfolio, providing baseline revenues while the Lyme and Shigella programs mature.

Valneva is a commercial-stage company generating product revenues, but its growth thesis is entirely pre-commercial — contingent on LB6V regulatory submissions and approval. The March 2026 Phase III VALOR topline data are the most advanced milestone achieved; Pfizer is now preparing regulatory filings, likely targeting FDA and EMA submissions in 2026-2027. Shigella4V data readouts are also expected in 2026. The company guides for full-year 2026 revenues of €155–170 million, reflecting existing product sales rather than any pipeline contribution.

The key watchpoints heading into 2026 and beyond are:

Pfizer's regulatory submission timing and eventual FDA/EMA decisions on LB6V — the single biggest value inflection point in the company's history.
Ongoing EMA PSUR surveillance of IXCHIQ concluding June 2026, which could further restrict or potentially rehabilitate the chikungunya franchise in Europe.
Shigella4V clinical data readouts, which will indicate whether Valneva has a credible third growth pillar.
The pace and cost of the Lyon manufacturing consolidation, and whether restructuring savings materialize as guided.
Any further pharmacovigilance findings with IXCHIQ's live-attenuated platform that could cast a shadow on Valneva's broader regulatory relationships.

Want to Update your Company's Profile?